The effects of heparins on the liver: Application of mechanistic serum biomarkers in a randomized study in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 2, 2012, Pages 214-220

  Harrill, A H ^a,b   Roach, J ^c   Fier, I ^c   Eaddy, J S ^a   Kurtz, C L ^a   Antoine, D J ^d   Spencer, D M ^e,f   Kishimoto, T K ^c   Pisetsky, D S ^e,f   Park, B K ^d   Watkins, P B ^a,b,g  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Momenta Pharmaceuticals Inc   (United States)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e DURHAM VA MEDICAL CENTER   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOMIPARIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CYTOKERATIN 18; DALTEPARIN; DNA; ENOXAPARIN; GLUTAMATE DEHYDROGENASE; HEPARIN; HIGH MOBILITY GROUP B1 PROTEIN; IDITOL DEHYDROGENASE; MICRORNA 122;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DNA DETERMINATION; HUMAN; LIVER; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ALANINE TRANSAMINASE; ANTICOAGULANTS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; DALTEPARIN; ENOXAPARIN; GLUTAMATE DEHYDROGENASE; HEPARIN; HMGB1 PROTEIN; HUMANS; KERATIN-18; L-IDITOL 2-DEHYDROGENASE; LIVER; MALE; MICRORNAS; MIDDLE AGED; YOUNG ADULT;

EID: 84864151938     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.40     Document Type: Article

References (35)

1. AL-Mekhaizeem, K.A. & Sherker, A.H. Heparin-induced hepatotoxicity. Can. J. Gastroenterol. 15, 527-530 (2001). (Pubitemid 32904339)
2. Dukes, G.E. Jr et al. Transaminase elevations in patients receiving bovine or porcine heparin. Ann. Intern. Med. 100, 646-650 (1984). (Pubitemid 14143936)
3. Fagher, B. & Lundh, B. Heparin treatment of deep vein thrombosis. Effects and complications after continuous or intermittent heparin administration. Acta Med. Scand. 210, 357-361 (1981). (Pubitemid 12212663)
4. Schwartz, K.A., Royer, G., Kaufman, D.B. & Penner, J.A. Complications of heparin administration in normal individuals. Am. J. Hematol. 19, 355-363 (1985). (Pubitemid 15004918)
5. Carlson, M.K., Gleason, P.P. & Sen, S. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecularweight heparin-induced hepatotoxicity. Pharmacotherapy 21, 108-113 (2001). (Pubitemid 32047579)
6. Christiansen, H.M. et al. Biologic tolerance of two different low molecular weight heparins. Semin. Thromb. Hemost. 17, 450-454 (1991).
7. Colwell, C.W. Jr et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J. Bone Joint Surg. Am. 76, 3-14 (1994). (Pubitemid 24081799)
8. Olsson, R., Korsan-Bengtsen, B.M., Korsan-Bengtsen, K., Lennartsson, J. & Waldenström, J. Serum aminotransferases after low-dose heparin treatment. Short communication. Acta Med. Scand. 204, 229-230 (1978). (Pubitemid 9024660)
9. A rora, N. & Goldhaber, S.Z. Anticoagulants and transaminase elevation. Circulation 113, e698-e702 (2006). (Pubitemid 43739383)
10. Kishimoto, T.K. et al. M118- A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes. Thromb. Haemost. 102, 900-906 (2009).
11. Rao, S.V. Et al.; EMINENCE Investigators. Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. Circulation 121, 1713-1721 (2010).
12. van der Wiel, H.E., Lips, P., Huijgens, P.C. & Netelenbos, J.C. Effects of shortterm low-dose heparin administration on biochemical parameters of bone turnover. Bone Miner. 22, 27-32 (1993). (Pubitemid 23272787)
13. Levy, S.W. Effects of heparin in vivo on lysosomal enzymes in rat plasma. Can. J. Biochem. 45, 1145-1151 (1967).
14. G irolami, B., Prandoni, P., Rossi, L. & Girolami, A. Transaminase elevations in patients treated with unfractionated heparin or low molecular weight heparin for venous thromboembolism. Clin. Appl. Thrombo. Hemost. 4, 126-128 (1998). (Pubitemid 28196396)
15. S hilo, S., Abraham, A.S., Breuer, R. & Sonnenblick, M. Hypertransaminasemia with subcutaneous heparin therapy. Isr. J. Med. Sci. 17, 1133-1135 (1981). (Pubitemid 12111501)
16. Luyendyk, J.P., Shaw, P.J., Green, C.D., Maddox, J.F., Ganey, P.E. & Roth, R.A. Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J. Pharmacol. Exp. Ther. 314, 1023-1031 (2005). (Pubitemid 41205965)
17. Harada, N., Okajima, K. & Uchiba, M. Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemiareperfusion-induced liver injury in rats. Crit. Care Med. 34, 1883-1891 (2006). (Pubitemid 43982463)
18. Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W. & Tuschl, T. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 12, 735-739 (2002). (Pubitemid 34455427)
19. S tarkey Lewis, P.J. et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54, 1767-1776 (2011).
20. Wetmore, B.A. et al. Quantitative analyses and transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury. Hepatology 51, 2127-2139 (2010).
21. S chmidt, E.S. & Schmidt, F.W. Glutamate dehydrogenase: biochemical and clinical aspects of an interesting enzyme. Clin. Chim. Acta 173, 43-55 (1988).
22. Ozer, J., Ratner, M., Shaw, M., Bailey, W. & Schomaker, S. The current state of serum biomarkers of hepatotoxicity. Toxicology 245, 194-205 (2008).
23. Linder, S., Havelka, A.M., Ueno, T. & Shoshan, M.C. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett. 214, 1-9 (2004). (Pubitemid 39141193)
24. S anders, S.W., Dukes, G.E. Jr, Gray, P. & Tolman, K.G. Toxicity of heparin in isolated rat hepatocytes. Biochem. Pharmacol. 33, 2223-2226 (1984). (Pubitemid 14090915)
25. Pisetsky, D.S. & Jiang, W. Role of Toll-like receptors in HMGB1 release from macrophages. Ann. N. Y. Acad. Sci. 1109, 58-65 (2007). (Pubitemid 47511345)
26. Rauvala, H. & Rouhiainen, A. Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors. Biochim. Biophys. Acta 1799, 164-170 (2010).
27. Evankovich, J. et al. High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J. Biol. Chem. 285, 39888-39897 (2010).
28. A ntoine, D.J. et al. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol. Sci. 112, 521-531 (2009).
29. Daly, A.K. Drug-induced liver injury: past, present and future. Pharmacogenomics 11, 607-611 (2010).
30. A dams, D.H., Ju, C., Ramaiah, S.K., Uetrecht, J. & Jaeschke, H. Mechanisms of immune-mediated liver injury. Toxicol. Sci. 115, 307-321 (2010).
31. Bezabeh, S., Flowers, C.M., Kortepeter, C. & Avigan, M. Clinically significant liver injury in patients treated with natalizumab. Aliment. Pharmacol. Ther. 31, 1028-1035 (2010).
32. Mancini, S., Amorotti, E., Vecchio, S., Ponz de Leon, M. & Roncucci, L. Infliximabrelated hepatitis: discussion of a case and review of the literature. Intern. Emerg. Med. 5, 193-200 (2010).
33. Watkins, P.B., Seligman, P.J., Pears, J.S., Avigan, M.I. & Senior, J.R. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 48, 1680-1689 (2008).
34. A ntoine, D.J. et al. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J. Hepatol. (2012); e-pub ahead of print 17 January 2012.
35. Kroh, E.M., Parkin, R.K., Mitchell, P.S. & Tewari, M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR) . Methods 50, 298-301 (2010).